Clinical and Translational Oncology

Aims & Scope

Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology.

It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs.

In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists.

Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series.

Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	2.5
2024	2.80

SJR (SCImago Journal Rank)

Year	Value
2024	0.903

Quartile

Year	Value
2024	Q2

h-index

Year	Value
2024	65

Journal Rank

Year	Value
2024	5675

Journal Citation Indicator

Year	Value
2024	2363

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology and Medicine, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Photodynamic therapy of cancer. Basic principles and applications

  Citation: 634

  Authors: Ángeles, Pedro, Francisco, Jesús, Salvador

• Natural products as leads to anticancer drugs

  Citation: 526

  Authors: M.

• Survival in glioblastoma: a review on the impact of treatment modalities

  Citation: 522

  Authors: P. D., E. M.

• Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma

  Citation: 242

  Authors: Higinia R., Tracy R., Susan M., Mary, P., T. E., Mark A., Tracey E., Kathy, Jill, Peter A. S.

• Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research

  Citation: 228

  Authors: Susana Patricia, Manuela, Rosa María, José Luis

• Exocrine pancreatic cancer: Symptoms at presentation and their relation to tumour site and stage

  Citation: 202

  Authors: Miquel, Xavier, Núria, Luisa, Alfredo, Ana, Laura, Manuel, Sergi, Susana, Juan, Josep M., Ricard, Antonio, Francisco X.

• Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer

  Citation: 201

  Authors: S., D., A., P., A., E., N., E.

• Emerging roles of aerobic glycolysis in breast cancer

  Citation: 196

  Authors: Z., J., Q., S., J.

• Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer

  Citation: 183

  Authors: Viren, Joanne, Anni, Anish

• Ki67 targeted strategies for cancer therapy

  Citation: 183

  Authors: C., J., M., K., L., L., J.

---